iBio Inc.

1.19
-0.01 (-0.83%)
At close: Apr 14, 2025, 1:00 PM
-0.83%
Bid 1.14
Market Cap 11.75M
Revenue (ttm) 375K
Net Income (ttm) -19.3M
EPS (ttm) 1.3
PE Ratio (ttm) 0.92
Forward PE -1.43
Analyst Buy
Ask 1.24
Volume 311,102
Avg. Volume (20D) 622,859
Open 1.21
Previous Close 1.20
Day's Range 1.17 - 1.23
52-Week Range 1.03 - 6.89
Beta 1.02

About IBIO

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing ...

Industry Biotechnology
Sector Healthcare
IPO Date Aug 19, 2008
Employees 16
Stock Exchange AMEX
Ticker Symbol IBIO
Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for IBIO stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 320.17% from the latest price.

Stock Forecasts